<?xml version="1.0" encoding="UTF-8"?>
<p>The primary inflammatory responses are usually mild and can be overcome by most patients. It is the secondary inflammatory response that is frequently florid and fatal. Though antiviral neutralizing antibodies enhance the clearance of the virus (as evidenced by the decrease in viral load), anti-spike protein-neutralizing antibodies (anti-S-IgG) in SARS-CoV infection have been found to cause severe lung injury by altering inflammatory responses in previous animal studies [
 <xref rid="B48-pharmaceuticals-13-00096" ref-type="bibr">48</xref>]. Similarly, the vaccine for SARS-CoV has been found to induce pulmonary injury in multiple animal models [
 <xref rid="B49-pharmaceuticals-13-00096" ref-type="bibr">49</xref>,
 <xref rid="B50-pharmaceuticals-13-00096" ref-type="bibr">50</xref>]. 
</p>
